Chris Robillard
Corporate Officer/Principal bei CRINETICS PHARMACEUTICALS, INC.
Profil
Chris Robillard is currently the Chief Business Officer at Crinetics Pharmaceuticals, Inc. He previously worked as the Vice President & Head of Business Development at Goldfinch Bio, Inc. and as the Head of Business Development & Corporate Strategy at Karyopharm Therapeutics, Inc. Mr. Robillard completed his undergraduate degree at Lehigh University and holds an MBA from Pepperdine University.
Aktive Positionen von Chris Robillard
| Unternehmen | Position | Beginn |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 21.03.2022 |
Ehemalige bekannte Positionen von Chris Robillard
| Unternehmen | Position | Ende |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | - |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Chris Robillard
| Lehigh University | Undergraduate Degree |
| Pepperdine University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
